• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Favorable outcomes achieved after toric IOL implantation in post-penetrating keratoplasty eyes

Article

Implantation of a toric IOL appears to be a safe and effective method for correcting spherical error and astigmatism in eyes with cataract and a history of penetrating keratoplasty, said Renée D. Solomon, MD.

Implantation of a toric IOL appears to be a safe and effective method for correcting spherical error and astigmatism in eyes with cataract and a history of penetrating keratoplasty, said Renée D. Solomon, MD.

Dr. Solomon presented outcomes from a prospective study of 10 eyes of 8 patients implanted with a toric IOL after surgery for a visually significant cataract. Inclusion criteria required that the eyes have refractive cylinder between 1 and 5 D after penetrating keratoplasty and have had the graft sutures removed at least 3 months previously. Eric Donnenfeld, MD, performed all of the cataract surgeries.

All eyes experienced improvements in best-corrected visual acuity (BCVA) and cylinder and statistically significant improvements were found in the mean values for both parameters. Mean BCVA improved from 20/70 preoperatively to 20/25 postoperatively. Mean cylinder improved from 3.37 to 1.27 D.

"We believe the reduction in cylinder achieved in these patients represents a significant improvement and supports further study of the implantation of toric IOLs as a method for visual rehabilitation of refractive errors in post-penetrating keratoplasty eyes with visually significant cataracts," Dr. Solomon said.

Related Videos
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.